Jazz Pharmaceuticals plc — Director's Dealing 2022

Jun 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-06-06

Reporting Person: Sablich Kim (EVP & GM, North America)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-06	Ordinary Shares	F	1759	$149.25	Disposed	28583	Direct
2022-06-06	Ordinary Shares	S	1388	$152.15	Disposed	27195	Direct
2022-06-07	Ordinary Shares	S	200	$148.209	Disposed	26995	Direct
2022-06-07	Ordinary Shares	S	250	$149.2249	Disposed	26745	Direct
2022-06-07	Ordinary Shares	S	573	$150.676	Disposed	26172	Direct
2022-06-07	Ordinary Shares	S	1317	$151.8725	Disposed	24855	Direct
2022-06-07	Ordinary Shares	S	101	$152.595	Disposed	24754	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.05 to $148.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.12 to $149.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.32 to $151.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $151.35 to $152.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.595 to $152.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.